New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

InterHealth highlights research backing new chromium formulation Zychrome

InterHealth has announced the next breakthrough in chromium research and development with the launch of Zychrome, a revolutionary new form of chromium.

InterHealth, often regarded as pioneers in the development of unique dietary chromium complexes, has announced the next breakthrough in chromium research and development with the launch of Zychrome™, a revolutionary new form of chromium. Zychrome™ represents the next generation chromium for maintaining normal insulin and blood sugar levels.

Zychrome™ was shown in a randomized, double blind, placebo-controlled study to significantly decrease insulin resistance and fasting insulin levels in diabetic subjects. Reductions of 30% were seen for both insulin parameters after three months of supplementation. Zychrome™ also significantly decreased inflammatory cytokine TNF-α level by 21%. Reductions in this metabolic marker may help lead to normal insulin and blood sugar control.

InterHealth started development of Zychrome™ over five years ago with the objective of creating the best possible chromium available. InterHealth tested 17 different chromium complexes for optimal benefits in metabolic function and for managing insulin resistance. According to InterHealth scientist, Francis Lau, PhD, “Zychrome™ is a unique form of chromium, niacin and L-cysteine called chromium dinicocysteinate. “Results from our preclinical work on Zychrome™, which have been published in Molecular Nutrition & Food Research, showed the utmost potential and suggested a clear advantage over other chromium forms in various metabolic parameters such as in decreasing insulin and blood sugar levels.” Safety research, including a 90-day oral toxicity study demonstrating Zychrome™’s broad-spectrum safety, has been published in Toxicology Mechanisms and Methods.

InterHealth CEO Paul Dijkstra said that the company is extremely excited with the results of the clinical data on Zychrome™. “This market has not seen anything new in over 20 years,” stated Dijkstra. “Zychrome™ will reinvigorate the blood sugar market as the next generation in chromium supplementation. The clinical results we’ve seen as well as the published preclinical data are very promising. This is a step in the right direction in managing insulin function and ultimately blood sugar control for millions of Americans.”

About InterHealth Nutraceuticals, Inc.

InterHealth Nutraceuticals researches, develops, markets and distributes specialty nutritional ingredients, which are sold worldwide to manufacturers of dietary supplements and nutraceutical food and beverage products. The company’s products include Zychrome™ for insulin modulation and function as well as LOWAT™, Super CitriMax®, UC-II®, ChromeMate®, Aller-7®, OptiBerry®, L-OptiZinc®, Protykin® and ZMA®. For more information about InterHealth and its products, call 1-800-783-4636 or 1-707-751-2800 (outside U.S.) or visit

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.